APGE
Price
$39.48
Change
-$0.88 (-2.18%)
Updated
May 23 closing price
Capitalization
2.3B
ERAS
Price
$1.22
Change
-$0.00 (-0.00%)
Updated
May 23 closing price
Capitalization
345.61M
75 days until earnings call
Interact to see
Advertisement

APGE vs ERAS

Header iconAPGE vs ERAS Comparison
Open Charts APGE vs ERASBanner chart's image
Apogee Therapeutics
Price$39.48
Change-$0.88 (-2.18%)
Volume$405.97K
Capitalization2.3B
Erasca
Price$1.22
Change-$0.00 (-0.00%)
Volume$933.42K
Capitalization345.61M
APGE vs ERAS Comparison Chart
Loading...
APGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APGE vs. ERAS commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APGE is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (APGE: $39.48 vs. ERAS: $1.22)
Brand notoriety: APGE and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APGE: 62% vs. ERAS: 55%
Market capitalization -- APGE: $2.3B vs. ERAS: $345.61M
APGE [@Biotechnology] is valued at $2.3B. ERAS’s [@Biotechnology] market capitalization is $345.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APGE’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • APGE’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, APGE is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APGE’s TA Score shows that 6 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • APGE’s TA Score: 6 bullish, 3 bearish.
  • ERAS’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, APGE is a better buy in the short-term than ERAS.

Price Growth

APGE (@Biotechnology) experienced а -2.81% price change this week, while ERAS (@Biotechnology) price change was -5.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

APGE is expected to report earnings on May 12, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APGE($2.3B) has a higher market cap than ERAS($346M). APGE YTD gains are higher at: -12.848 vs. ERAS (-51.394). ERAS has higher annual earnings (EBITDA): -151.33M vs. APGE (-216.68M). APGE has more cash in the bank: 521M vs. ERAS (319M). APGE has less debt than ERAS: APGE (11.8M) vs ERAS (52.9M). APGE (0) and ERAS (0) have equivalent revenues.
APGEERASAPGE / ERAS
Capitalization2.3B346M665%
EBITDA-216.68M-151.33M143%
Gain YTD-12.848-51.39425%
P/E RatioN/AN/A-
Revenue00-
Total Cash521M319M163%
Total Debt11.8M52.9M22%
TECHNICAL ANALYSIS
Technical Analysis
APGEERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 23 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
APGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRLHX22.47N/A
N/A
Nuveen Large Cap Value I
RMATX11.01N/A
N/A
Russell Inv Multi-Asset Strat M
FGEMX110.05N/A
N/A
Fidelity Advisor Communication ServicesM
BUFGX33.95N/A
N/A
Buffalo Growth
CLPCX12.04N/A
N/A
Catalyst Nasdaq-100 Hedged Equity C

APGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APGE
1D Price
Change %
APGE100%
-2.18%
SYRE - APGE
53%
Loosely correlated
-0.40%
ELVN - APGE
52%
Loosely correlated
-3.13%
ERAS - APGE
52%
Loosely correlated
N/A
ATXS - APGE
51%
Loosely correlated
N/A
CRNX - APGE
51%
Loosely correlated
-1.16%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
N/A
XNCR - ERAS
58%
Loosely correlated
-1.56%
RVMD - ERAS
55%
Loosely correlated
+2.50%
KYMR - ERAS
55%
Loosely correlated
-2.12%
RCKT - ERAS
54%
Loosely correlated
-4.86%
BEAM - ERAS
54%
Loosely correlated
-2.26%
More